I suspect the epigenetic rejuvenation we see with α-Ketoglutarate (AKG) isn't just about systemic concentration; it's a circadian-gated phenomenon. My hypothesis is that TET enzyme-mediated DNA demethylation is controlled by the oscillation of BMAL1:CLOCK binding to TET promoters. In aging, the drop in systemic AKG GeneticLifeHacks mirrors the dampening of these oscillations. If you take high-dose AKG out of sync with these rhythms, you likely won't activate TETs effectively. Conversely, pulse-dosing timed to the trough of the circadian cycle should trigger much more significant epigenetic clock reversals.

We treat AKG as a limiting cofactor for TET enzymes Science Advances, but we’ve been ignoring the enzymatic stoichiometry. Since TET1 and TET2 are under the transcriptional control of core circadian clock proteins, chromatin remodeling windows are likely restricted to specific phases. Systemic AKG available outside that window is probably just wasted, or diverted into the TCA cycle for ATP production rather than doing any epigenetic work.

I also suspect a feedback loop exists, which I call the "Epigenetic Scarring Hypothesis." In aging, chronic, mistimed nutrient flux leads to the silencing of TET promoters via methylation-sensitive transcription factors. By aligning exogenous AKG with the endogenous NAD+ peak—typically in the early morning or before breaking a fast—we might overcome the high Km of TET enzymes for AKG right when their transcription peaks. This would effectively "prime" the epigenome to reset during the restorative phase of the diurnal rhythm.

To test this, we need to move past fixed-dose protocols ClinicalTrials.gov and use a crossover design:

1. The Pulse-Phase Trial: Compare identical daily doses of Ca-AKG administered in the morning (peak metabolic shift) versus the evening (metabolic nadir).
2. Mechanistic Endpoint: Using CRISPR-tagged TET reporter cell lines or high-resolution ChIP-seq in PBMCs, track TET occupancy at "age-drift" CpG sites immediately following pulse vs. sustained-release dosing.
3. Falsification: If biological age—measured via Horvath-style clocks—doesn't change regardless of timing, we have to reject the idea that TET activity is a circadian-gated process. It would mean AKG-driven rejuvenation is simply a result of a broader, non-temporal metabolic threshold.

If we want to get past the hype of observational studies NovosLabs, we have to figure out if TET activation is a stochastic mass-action event or something more precise. If we ignore the temporal component, we’re trying to perform a surgical-grade epigenetic intervention using the blunt instrument of chronic, undifferentiated supplementation.